Human Studies on Relapse Prediction in Multiple Sclerosis
A systematic review included 14 studies focused on models predicting relapse in multiple sclerosis. These studies explored conventional relapse prognosis, individualized treatment effects, and relapse-related outcomes. The models developed showed moderate accuracy but often lacked robust external validation.
- Tags
- #MSResearch
- Most relevant to
- —
Why it matters
This review highlights potential avenues for improving relapse prediction models in multiple sclerosis, an important area for patient management. However, the findings underscore that the current evidence is inconsistent and needs further validation.
What this does not prove
The evidence remains heterogeneous and insufficiently validated for routine clinical use. Improvements are needed in defining outcomes, reporting calibration, and validating models across diverse clinical populations.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Systematic review
- Participants / samples
- 14 · basis not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-04
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
- Primary evidenceRelapse prediction and individualized treatment-effect modeling in relapsing multiple sclerosis: a systematic review. ↗DOI: 10.3389/fpubh.2026.1940704
Supporting passages (6)
study designMETHODS: We conducted a systematic review in accordance with PRISMA 2020.
subjectsStudies developing or evaluating models for relapse or relapse-related outcomes in relapsing multiple sclerosis were included.
sample sizeRESULTS: Fourteen studies were included: five conventional relapse-prognosis studies, four individualized treatment-effect prediction studies, and five exploratory relapse-related studies.
publication date2026-09-04
findingsClinically interpretable models based on structured clinical data generally demonstrated moderate discrimination but more transparent validation.
limitationsDISCUSSION: Relapse-related prediction in multiple sclerosis is feasible, but current evidence remains heterogeneous and insufficiently validated for routine clinical implementation.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.